《大行》華泰證券上調康方生物(09926.HK)目標價至205.69元 業績增長邏輯清晰
華泰證券發表報告,對康方生物(09926.HK)目標價由115.25元上調至205.69元,維持「買入」評級。
報告指,康方生物中期業績明確依沃西單抗在HARMONi-A研究中獲得OS統計學和臨牀獲益顯着。商業化方面,上半年收入按年升37.8%至14.1億元人民幣,其中產品銷售按年升49.2%至14億元人民幣,淨虧損5.9億元人民幣,包括投資損失1.6億元人民幣,手上現金65.9億元人民幣。
該行認爲公司業績增長邏輯清晰,包括依沃西單抗在OS獲益支撐下,同類最佳地位築牢,醫保賦能下具增長動力,以及兩大核心品種全面推動海外臨牀,進軍全球市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.